Comparison of children hospitalized with enterovirus or human parechovirus (HPeV) detected in their cerebrospinal fluid revealed that HPeV infections presented with more persistent fever, irritability and feeding problems, more frequent leukopenia and lymphopenia and higher admission rates to high dependency or intensive care units. Few HPeV cases were followed up, further studies on long-term outcomes are needed.
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EVs and human parechoviruses (HPeVs) are nonenveloped, single-stranded, positive-sense RNA viruses and members of the Picornavirus family. They are common causes of neonatal and infant sepsis, worldwide.
EVs exist as multiple serotypes, subdivided into various genus, including echoviruses, Coxsackie A and B viruses and the numbered EVs. HPeVs exist in at least 17 genotypes, of which genotypes 1-6 are most commonly found in humans, with genotype 3 being most commonly responsible for sepsis in neonates and infants.
Whereas most episodes of EV and HPeV neonatal and infant sepsis are self-limiting, more severe illness can occur, and there are current concerns regarding longer term sequelae, particularly in HPeV infections, where there is more significant neurologic involvement. Previous studies have found that the clinical presentation of the 2 viruses are often indistinguishable. 1, 3 Our diagnostic virology laboratory has only recently (since mid 2014) introduced routine testing for parechoviruses as part of our neonatal and infant sepsis workup. We examined the demographics, laboratory results and clinical notes for pediatric patients admitted with sepsis with laboratory-confirmed human EV or HPeV infections of the cerebrospinal fluid (CSF), during February 2014 to August 2017. recent reports of decrease in MRSA infections in children across the United States and internationally. 7, 8 However, hospital and CA-MRSA infections still remain concerning global public health issues. [7] [8] [9] The purpose of the 48-hour time bound sample collection was to capture colonization acquired in the community and not during the admission in the hospital. While lesser MRSA and MSSA colonization rates in a community likely translate to lesser S. aureus infections, as we found in our study, both MRSA and MSSA infections could still occur in individuals without underlying nasal S. aureus colonization who may be colonized in other areas of the body.
METHODS

All cases from
A noteworthy limitation to the comparability of this study and the 2005 DCH study is the difference in the sampling window between the 2 studies. The 2005 study sample was conveniently collected from February to March, whereas the samples for this study were conveniently collected from April to November. The daily emergency room encounters and admission rates at DCH were roughly stable between the 2 studies. However, MRSA have been reported to be seasonal, and the fluctuation in the incidence of MRSA between seasons may have obscured our findings.
We noted that the overall S. aureus colonization rate in 2016 compared with 2005 decreased largely because of the decline in the MRSA colonization proportion. Our findings, thus, bring forth the question as to what actually caused the decrease in the MRSA colonization proportion. Because of the epidemic of MRSA infections, many clinicians adopted precautionary approaches to their clinical practices. There has been a shift toward empiric prescription of antibiotics effective against MRSA, such as clindamycin, trimethoprim-sulfamethoxazole and vancomycin, for skin and soft tissue infections before definitive culture results are available. 10 We do not know the reason for the observed decrease in the prevalence of pediatric nasal MRSA colonization, but clinicians' antibioticsprescribing practices may have contributed.
either EV or HPeV RNA, using assays previously described elsewhere, 2,4 which were performed as part of the routine workup for neonates or infants admitted with suspected sepsis. Additional samples were taken depending on the degree of clinical illness, including ethylenediaminetetraacetic acid blood, rectal swabs or stool samples and various respiratory samples (nasopharyngeal aspirates, throat swabs and bronchoalveolar lavages). For each patient, their laboratory values were extracted from the laboratory database, and clinical notes were reviewed.
This study was performed as part of a pediatric departmental audit which aimed to ensure that all EV-and HPeV-infected pediatric patients had received appropriate follow-up after discharge for sepsis, where there was laboratory-confirmed EV or HPeV infection of the CSF. Formal ethics approval was not required.
Clinical indices examined included age at presentation, length of stay, fever, rash, seizures, respiratory difficulty, feeding problems, antimicrobial use and admission to high dependency unit (HDU) or intensive care unit (ICU). Laboratory values compared included C-reactive protein, white cell counts (WCC), liver function tests, CSF profile (glucose, protein and cell counts) and radiologic investigations, where available.
Clinical and laboratory characteristics were compared between patients with HPeV and EV infection. Continuous variables were presented as mean and standard deviation (or median and interquartile range, if not normally distributed) and compared with Student's t test (or Wilcoxon test). Binary variables were presented as frequency and percentages and compared with the Fisher exact test. Multivariable analysis for risk ratios (RRs) comparing HPeV infection with EV infection as the reference was estimated using log-Binomial regression model.
RESULTS
There were no statistically significant differences in age or sex of the children affected by EV versus HPeV central nervous system infections, but there appeared to be a difference in range, with EV often affecting older children than HPeV (interquartile range: 29-102 days for EV and 25.5-61 days for PeV).
Of a total of 163 cases, there were 131 EV (ie, 7 Coxsackie A, 18 Coxsackie B, 46 echoviruses, with 60 EVs that could not be typed further) and 32 HPeV infections (Table 1 ). All HPeV infections were caused by HPeV genotype 3. Of the EV cases, 73% (95 cases) were in children younger than 90 days (3 months), whereas greater than 90% (30 cases) of HPeV cases were in children younger than 90 days (3 months).
Cases of EV meningitis showed 3 peaks of activity each year with the most significant being in November to December. In contrast, HPeV had only 1 significant outbreak during 2 months in summer 2016 (Fig., Supplemental Digital Content 1 , http://links. lww.com/INF/D223). There was no difference in the mean age or sex of the children affected by EV or PeV, although there was a difference in range, with EV meningitis affecting some older children.
A greater number of abnormal indices were found with HPeV than for EVs, with a greater likelihood of admission to HDU/ ICU (P = 0.004) and a higher rate of persistent symptoms (ie, fever, irritability and feeding problems, P < 0.05). Compared with children infected with EV, children with HPeV were more likely to have an abnormally low WCC (leukopenia) (56% HPeV vs. 14% EV, P < 0.001) and an abnormally low lymphocyte count (lymphopenia) (91% HPeV vs. 39% EV, P < 0.001) (Table, Supplemental Digital Content 2, http://links.lww.com/INF/D224).
In contrast, EV cases were more likely to have a high WCC in the CSF (6% HPeV vs. 50% EV, P < 0.001) (Table, Supplemental Digital Content 3, http://links.lww.com/INF/D225). In the adjusted (log-Binomial regression) analysis, the HPeV cases were over 5 more times more likely to have lymphopenia than EV cases (RR = 5.11; 95% confidence interval: 1.53-17.05; P = 0.008), with EV cases being marginally more likely to have a higher CSF WCC (RR = 0.22; 95% confidence interval: 0.05-0.92; P = 0.038) (Table, Supplemental Digital Content 4, http://links.lww.com/INF/D226).
Other laboratory and clinical indices, including overall length of stay, did not differ significantly between the EV or HPeV cases. There was no significant difference in whether or not EV or HPeV cases received antibiotic (98.4% vs. 100%, respectively, P = 0.999) and/or acyclovir (37.1% vs. 34.4%, respectively, P = 0.839) treatment (Table, Supplemental Relatively few patients were deemed to require longer term follow-up. Of the total number of cases, 80% of children did not require any follow-up at 1 year post infection. At 1 year post infection, 3% of children were receiving follow-up by ophthalmology, with no abnormalities detected. Sixteen children (~10%) attended a routine hearing check, but none had any detectable sensorineural hearing loss. Only 3 patients (<2%) were reported as having had any developmental delay problems on admission: 1 child had delayed speech and manipulative skills-both of which resolved by 1 year post infection. Another child had some speech delay at 1 year follow-up, and 1 child had gross motor delay (despite a normal magnetic resonance imaging). As 2 of the 3 children with developmental problems had uncomplicated, short inpatient stays, this might suggest that their viral infections were not direct causes of this. However, this does not completely exclude this etiologic possibility.
DISCUSSION
Infections by EVs and HPeVs are well-documented causes of neonatal and infant sepsis. However, relatively few studies have compared the severity of clinical illness caused by these viruses within the same pediatric population within the same season. 5 Here, we demonstrate differences in presentation and severity of these 2 viruses, with HPeV cases having a higher likelihood of having persistent fevers (P < 0.05), irritability or feeding problems (P < 0.05), leukopenia, lymphopenia and requiring admission to pediatric HDU or ICU units than children with EV infections. These findings are consistent with those reported from other studies. [6] [7] [8] In 
